In 2013, Lesaffre Human Care (LHC) finalized a strategic plan that resulted in an ambitious growth strategy for enlarging LHC’s ingredient range, based on microorganisms and biotechnology, for the nutrition, health and beauty market. In that context, the company has announced the acquisition of Omniabios. Omniabios is an Italian company that has expertise in producing the molecule S-Adenosyl-L-methionine, known as SAM-e.